Quick Answer
AIM ImmunoTech Inc. reported R&D Expense of $3.92 million for fiscal year 2025.
AIM ImmunoTech Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $3.92M | -36.7% |
| 2024 | $6.20M | -43.3% |
| 2023 | $10.94M | +56.5% |
| 2022 | $6.99M | -8.9% |
| 2021 | $7.67M | +34.1% |
| 2020 | $5.72M | +23.0% |
| 2019 | $4.65M | -2.7% |
| 2018 | $4.78M | +16.6% |
| 2017 | $4.10M | -19.8% |
| 2016 | $5.11M | -36.5% |
| 2015 | $8.04M | -10.6% |
| 2014 | $8.99M | +7.5% |
| 2013 | $8.36M | -12.1% |
| 2012 | $9.51M | +41.4% |
| 2011 | $6.72M | -11.7% |
| 2010 | $7.61M | +8.8% |
| 2009 | $7.00M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $607.0K | -57.8% | -48.3% |
| June 30, 2025 | $1.17M | +2.5% | +8.7% |
| March 31, 2025 | $1.08M | -44.6% | -24.8% |
| September 30, 2024 | $1.44M | -47.4% | +25.5% |
| June 30, 2024 | $1.15M | -61.2% | -41.3% |
| March 31, 2024 | $1.95M | -4.9% | -28.6% |
| September 30, 2023 | $2.73M | +99.3% | -7.4% |
| June 30, 2023 | $2.95M | +19.3% | +43.9% |
- AIM ImmunoTech Inc. showed a decrease of -36.7% in R&D Expense compared to the prior fiscal year.
- Over the 2009–2025 period, AIM ImmunoTech Inc.’s r&d expense has declined by 43.9% (from $7.00 million to $3.92 million).
- The most recent figure is from AIM ImmunoTech Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 27, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: